B
Bull
Bull · 25%ANAB
$53.20
Szenariopreis
$56.280
-0.991 (-1.76%)Zum Schluss
Loading chart…
- High
- 57.240
- Open
- 57.240
- VWAP
- 56.30
- Vol
- 358.57K
- Mkt Cap
- 677.50M
- Low
- 55.375
- Amount
- 20.19M
- EV/EBITDA, TTM
- -8.67
AnaptysBio, Inc. is a royalty management company. The Company manages the financial collaborations for Jemperli with GlaxoSmithKline (GSK) and imsidolimab with Vanda Pharmaceuticals Inc. (Vanda). The Company's financial collaboration with GSK is focused upon the development and commercialization of Anaptys-discovered Jemperli (dostarlimab), a PD-1 antagonist, approved for endometrial cancer and dMMR pan tumors, and is being studied in rectal cancer, colon cancer and head and neck squamous cell carcinoma. The Company's financial collaboration with Vanda is focused upon the development and commercialization of Anaptys-discovered imsidolimab, an IL-36R antagonist, which is being developed for generalized pustular psoriasis (GPP).
AI analysis of AnaptysBio, Inc. (ANAB)
holdAnaptysBio Inc is currently at a price of $56.28 with a forward P/E of 0, indicating potential for future earnings but also uncertainty. The RSI is at 36.949, suggesting it is nearing oversold conditions, which could indicate a buying opportunity. However, the company reported a disappointing Q1 EPS of -1.84, missing expectations significantly, which raises concerns about its profitability and future cash flow. The main risk is the ongoing litigation with Tesaro, which could impact its market position and revenue from the Jemperli product, currently approved in over 35 countries.
Analyst Ratings (8)
+31.72% upside
Buy
8 Buy
0 Hold
0 Sell
Current: 56.28
Tief
50.00
Durchschnitt
74.13
Hoch
140.00
TD Cowen
Buy
$70
2026-08-25
TD Cowen
2026-08-25
Kursziel
$70
Buy
Leerink
Outperform
$90
2026-05-15
Leerink
2026-05-15
Kursziel
$90
Outperform
UBS
Buy
$76
2026-05-13
UBS
2026-05-13
Kursziel
$76
Buy
Barclays
Overweight
$75
2026-05-13
Barclays
2026-05-13
Kursziel
$75
Overweight
Piper Sandler
Overweight
$93
2026-05-04
Piper Sandler
2026-05-04
Kursziel
$93
Overweight
Bewertungskennzahlen
The current forward P/E ratio for AnaptysBio, Inc. (ANAB) is 0.00, compared to its 5-year average forward P/E of -3.99.
Alphio AI Price Scenarios for ANAB
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding ANAB
Event-Zeitleiste
News
9.505-12seekingalphaAnaptysBio Q1 Earnings Report Analysis
5.005-11NewsfilterAnaptysBio Strengthens Leadership Team and Board
9.004-28PRnewswireVanda Pharmaceuticals Publishes Imsidolimab Research Findings
9.004-28NewsfilterVanda Pharmaceuticals Announces Imsidolimab Research Findings
7.004-27seekingalphaTesaro and AnaptysBio Litigation Update
ANAB FAQ — answered by Alphio AI
AnaptysBio, Inc. is a royalty management company. The Company manages the financial collaborations for Jemperli with GlaxoSmithKline (GSK) and imsidolimab with Vanda Pharmaceuticals Inc. (Vanda). The Company's financial collaboration with GSK is focused upon the development and commercialization of Anaptys-discovered Jemperli (dostarlimab), a PD-1 antagonist, approved for endometrial cancer and dMMR pan tumors, and is being studied in rectal cancer, colon cancer and head and neck squamous cell carcinoma. The Company's financial collaboration with Vanda is focused upon the development and commercialization of Anaptys-discovered imsidolimab, an IL-36R antagonist, which is being developed for generalized pustular psoriasis (GPP). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
AnaptysBio Inc is currently at a price of $56.28 with a forward P/E of 0, indicating potential for future earnings but also uncertainty. The RSI is at 36.949, suggesting it is nearing oversold conditions, which could indicate a buying opportunity. However, the company reported a disappointing Q1 EPS of -1.84, missing expectations significantly, which raises concerns about its profitability and future cash flow. The main risk is the ongoing litigation with Tesaro, which could impact its market position and revenue from the Jemperli product, currently approved in over 35 countries.
8 analysts cover ANAB: 8 rate it Buy, 0 Hold and 0 Sell. The average price target is 74.13.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.